Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Frazier Life Sciences Acquisition Corp. II (FLSC)

Frazier Life Sciences Acquisition Corp. II closes $75 million IPO on Oct. 15

Neutral Impact 3 of 5 financing Written later

Frazier Life Sciences Acquisition Corp. II, a Cayman Islands blank check company, closed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share on October 15, 2026, for gross proceeds of $75 million. The full $75 million was placed in a U.S. trust account, and the company said it has not selected a business combination target, so shareholders' funds remain in the trust until a deal is completed or the company liquidates.

Key points

  • IPO: 7,500,000 Class A ordinary shares at $10.00 per share, gross proceeds of $75,000,000, closed October 15, 2026
  • Private placement: 300,000 Class A ordinary shares to the sponsor for gross proceeds of $3,000,000
  • Trust account: $75,000,000 held with Continental Stock Transfer & Trust Company as trustee
  • Balance sheet as of October 15, 2026 showed cash of $1,762,481 and a $3,000,000 deferred underwriting fee payable

The filing

CompanyFrazier Life Sciences Acquisition Corp. II (FLSC)
Form8-K, current report
Filed with the SECOct 22, 2026, 5:24 PM ET
Accession number0001193125-26-429129

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.